WO2011081383A2 - 나프토퀴논계 화합물을 포함하는 난청의 치료 또는 예방을 위한 조성물 - Google Patents
나프토퀴논계 화합물을 포함하는 난청의 치료 또는 예방을 위한 조성물 Download PDFInfo
- Publication number
- WO2011081383A2 WO2011081383A2 PCT/KR2010/009369 KR2010009369W WO2011081383A2 WO 2011081383 A2 WO2011081383 A2 WO 2011081383A2 KR 2010009369 W KR2010009369 W KR 2010009369W WO 2011081383 A2 WO2011081383 A2 WO 2011081383A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- compound
- aryl
- Prior art date
Links
- 0 *C(*)(*1)C(*)(*)*(*)(*)C(C2=O)=C1c(c(*)c(*)c(*)c1*)c1C2=O Chemical compound *C(*)(*1)C(*)(*)*(*)(*)C(C2=O)=C1c(c(*)c(*)c(*)c1*)c1C2=O 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention relates to a composition for the treatment or prevention of deafness comprising a naphthoquinone-based compound.
- Corticoids an auditory epithelial group arranged on the basement membrane of the cochlea (cochlea) of the inner ear, function as auditory hair cells, the smallest number of sensory receptor cells of all sensory tissues.
- Human cochlea have only 20,000 sensory receptors compared to the retina with 137,000,000 visual sensory receptors.
- auditory hair cells are produced only during embryonic development and are not regenerated if lost after birth. Thus, the loss of hair cells causes obvious and irreversible hearing damage.
- Hearing impairments include trauma, aging, excessive noise and pollution, toxic drugs such as antibiotics (e.g. gentamicin), loop diuretics, and platinum-based anticancer drugs (e.g. cisplatin), infections, autoimmune diseases and genetic diseases.
- toxic drugs such as antibiotics (e.g. gentamicin), loop diuretics, and platinum-based anticancer drugs (e.g. cisplatin)
- infections e.g. cisplatin
- autoimmune diseases e.g. cisplatin
- Cell death of auditory hair cells caused by various such causes has been found to be a major cause.
- NMDA N-methyl-D-aspartate
- naphthoquinone compounds are known as active ingredients of some pharmaceutical compositions.
- beta-lapaconone ⁇ -lapachone
- Laphacho tree Tabebuia avellanedae
- duneone and alpha-dunnione are grown in South America. Obtained from the leaves of Streptocarpus dunnii.
- Such natural tricyclic naphthoquinone derivatives have long been widely used in South America as a medicine for treating Chagas disease, a representative endemic disease in South America, including anticancer drugs. It is also known to be outstanding.
- the present inventors have conducted extensive studies to develop drugs that can treat or prevent hearing damage caused by aging, toxic drugs, and the like. As a result, the present inventors have found out that naphthoquinone-based compounds are effective in the treatment or prevention of hearing damage. Was done.
- the present invention relates to a composition for the treatment or prevention of hearing loss, comprising a compound of formula 1 or 2, a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof.
- R 1 to R 6 are each independently hydrogen, hydroxy, halogen, amino, substituted or unsubstituted C 1 -C 10 alkylamino, substituted or unsubstituted C 1 -C 10 dialkylamino, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 -C 10 alkenyl, substituted or unsubstituted C 2 -C 10 alkynyl, substituted or unsubstituted C 1 -C 10 alkoxy, substituted or unsubstituted C 1 -C 10 alkoxycarbonyl, substituted or unsubstituted C 1 -C 10 acyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 heterocycloalkyl, substituted or Unsubstituted C 4 -C 10 aryl, substituted or unsubstituted C
- R 7 to R 10 are each independently hydrogen, hydroxy, halogen, amino, substituted or unsubstituted C 1 -C 10 alkylamino, substituted or unsubstituted C 1 -C 10 dialkylamino, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 -C 10 alkenyl, substituted or unsubstituted C 2 -C 10 alkynyl, substituted or unsubstituted C 1 -C 10 alkoxy, substituted or unsubstituted C 1 -C 10 alkoxycarbonyl, substituted or unsubstituted C 1 -C 10 acyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 heterocycloalkyl, substituted or Unsubstituted C 4 -C 10 aryl, substituted or unsubstituted C
- substituents are hydroxy, halogen, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 alkoxy, C 1 -C 10 alkoxycar At least one selected from the group consisting of carbonyl, C 1 -C 10 alkylamino, C 3 -C 8 cycloalkyl, C 3 -C 8 heterocycloalkyl, C 4 -C 10 aryl, and C 4 -C 10 heteroaryl And;
- X is O, S or NR ', wherein R' is hydrogen or C 1 -C 6 alkyl
- Y is C, S, N or O, where R is Y or S 5 And R 6 Is Not any substituent, and if Y is N 5 Silver hydrogen or C One -C 6 Alkyl and R 6 Is not any substituent;
- n 0 or 1
- m 0 or 1
- n is an integer of 0-10.
- X is O or S
- Y may be C or O.
- R 1 to R 6 are each independently hydrogen, hydroxy, halogen, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 -C 10 alkenyl, substituted or unsubstituted C 1 -C 10 alkoxy, and - (CH 2) n - phenyl, or selected from the group consisting of, R 1 and R 4 or R 2 and R 3 double bond consisting of the interconnected or C 4 -C 6 It may be a ring structure of, wherein the substituent may be C 1 -C 10 Alkyl.
- each of R 7 to R 10 is independently a group consisting of hydrogen, hydroxy, halogen, substituted or unsubstituted C 1 -C 10 alkyl, and substituted or unsubstituted C 1 -C 10 alkoxy Can be selected from.
- Preferred examples of the compound of Formula 1 or 2 include a compound of Formula 1-1 or 2-1 wherein X is O and Y is C, or a compound of Formula 1-2 or 2-2 wherein X is S have.
- R 1 to R 10 , Y and m are the same as defined in Chemical Formula 1.
- the compound of Formula 1 or 2 may be a compound of formula 1-3 or 2-3 wherein m is 0 and adjacent carbon atoms form a cyclic structure (furan ring) by a direct bond.
- 'furan compound' or 'furano-o-naphthoquinone derivative' may be a compound of formula 1-3 or 2-3 wherein m is 0 and adjacent carbon atoms form a cyclic structure (furan ring) by a direct bond.
- R 1 to R 10 , and X are as defined in Formula 1 above.
- the compound of Formula 1 or 2 may be a compound of Formula 1-4 or 2-4 with m is 1.
- 'pyran compound' or 'pyrano-o-naphthoquinone derivative' may be a compound of Formula 1-4 or 2-4 with m is 1.
- R 1 to R 10 , X, and Y are the same as defined in Chemical Formula 1.
- the compound of Formula 1 or 2 is a compound of Formula 1-5 or 1-6 or R 7 and R 8 are connected to each other to form a ring structure of the formula 2-5 or 2-6 Compound.
- R 1 to R 10 , X, Y, and m are as defined in Formula 1,
- R 11 to R 18 are hydrogen, hydroxy, halogen, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 alkoxy, C 1 -C 10 alkoxycar Carbonyl, C 1 -C 10 alkylamino, C 3 -C 8 cycloalkyl, C 3 -C 8 heterocycloalkyl, C 4 -C 10 aryl, or C 4 -C 10 heteroaryl.
- R 11 to R 18 are each independently hydrogen, hydroxy, halogen, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 alkoxy, C 3 -C 8 cycloalkyl, or phenyl.
- the term "pharmaceutically acceptable salt” means a formulation of a compound that does not cause severe irritation to the organism to which the compound is administered and does not impair the biological activity and properties of the compound.
- the pharmaceutically acceptable salts include acids that form non-toxic acid addition salts containing pharmaceutically acceptable anions, such as inorganic acids, tartaric acid, such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, and the like.
- Organic carbon acids such as formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc., methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfate Acid addition salts formed by sulfonic acids and the like such as phonic acid and the like.
- base addition salts include alkali metal salts or alkaline earth metal salts formed by lithium, sodium, potassium, calcium, magnesium, and the like, amino acid salts such as lysine, arginine, guanidine, dicyclohexylamine, N-methyl-D-glucamine, Organic salts such as tris (hydroxymethyl) methylamine, diethanolamine, choline and triethylamine and the like.
- the compound of formula 1 or 2 according to the invention can be converted to its salts by conventional methods.
- prodrug refers to a substance that is transformed into a parent drug in vivo. Prodrugs are often used because they are easier to administer than the parent drug. For example, they may obtain physiological activity by oral administration, whereas the parent drug may not. Prodrugs may also have improved solubility in pharmaceutical compositions than the parent drug.
- a prodrug may be a compound administered as an ester that facilitates passage of a cell membrane, in which the water solubility is detrimental to mobility, but once the water solubility is beneficial, the cell is hydrolyzed to the active carboxylic acid by metabolism will be.
- prodrug may be a short peptide (polyamino acid) that is bound to an acid group that is converted by metabolism to reveal the active site.
- Prodrugs of the present invention include, but are not limited to, the compounds described in International Publication WO06 / 020719.
- solvate refers to a stoichiometric or non-stoichiometric amount bound by a non-covalent intermolecular force. It means a compound of the present invention or a salt thereof containing a solvent. Preferred solvents are those solvents which are volatile, non-toxic, and / or suitable for administration to humans, where the solvent is water, meaning hydrate.
- compound of formula 1 or 2 or "naphthoquinone-based compound” is a concept including the compound itself, pharmaceutically acceptable salts, prodrugs, solvates and isomers thereof. Used as
- alkyl means a radical that is free of unsaturated groups and contains carbon and hydrogen.
- Alkyl radicals may be straight (linear) or branched (branched).
- Exemplary alkyls include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, sec-butyl and the like.
- C 1 -C 10 alkyl is an alkyl group having 1 to 10 carbon atoms in a straight or branched chain alkyl backbone.
- Alkyl groups may be optionally substituted. When substituted, the alkyl group may be substituted with up to four substituents at any particular point of attachment (at any given carbon atom).
- alkyl group when the alkyl group is substituted with an alkyl group, it is used in the same sense as the "branched chain alkyl group".
- alkenyl refers to an unsaturated aliphatic group that is similar in length and substitution to an alkyl as described above, but contains one or more carbon-carbon double bonds.
- alkenyl includes straight chain alkenyl groups (eg, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, desenyl), branched alkenyl groups, and cycloalkenyl groups (Eg, cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl).
- alkenyl may further include alkenyl groups that include oxygen, nitrogen, sulfur or phosphorus atoms to replace one or more hydrocarbon backbone carbons.
- straight or branched alkenyl groups may have up to 6 carbon atoms in the main chain (eg, C 2 -C 6 for straight chains and C 3 -C 6 for branched chains).
- the cycloalkenyl group may have 3 to 8 carbon atoms in the ring structure, more preferably 5 to 6 carbon atoms.
- alkynyl refers to an unsaturated aliphatic group that is similar in length and substitution to alkyl as described above, but contains one or more carbon-carbon triple bonds.
- alkynyl refers to straight chain alkynyl groups (eg, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octinyl, noninyl, decinyl), and branched alkynyl groups (alkyl or alkyn) A kenyl substituted alkynyl group).
- alkynyl may further comprise an alkynyl group comprising an oxygen, nitrogen, sulfur or phosphorus atom replacing one or more hydrocarbon backbone carbons.
- straight or branched chain alkynyl groups have up to 6 carbon atoms in the main chain (eg, C 2 -C 6 for straight chains and C 3 -C 6 for branched chains).
- the substituents are, for example, hydroxy, carboxylate, oxo, halogen (eg F, Cl, Br, I), C 1 -C 6 halo Alkyl (eg, CCl 3 or CF 3 ), carbamoyl (-NHCOOR or -OCONHR), urea (-NHCONHR), thiol, cyano, nitro, amino, acylamino, C 1 -C 10 alkylthio, C 4 -C 10 arylthio, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 4 -C 10 aryloxy, C 1 -C 10 alkylcarbonyloxy, C 4 -C 10 arylcarbonyloxy, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyloxy, C 2 -C 10 alkenyl, C 2 -C 10
- cycloalkyl is an alkyl species containing 3 to 15 carbon atoms, preferably 3 to 8 carbon atoms, without alternating or resonant double bonds between the carbon atoms. Cycloalkyls can include 1 to 4 rings. Exemplary cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like. Exemplary substituents of cycloalkyl include halogen, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, amino, nitro, cyano, thiol, C 1 -C 10 alkylthio, and the like.
- heterocycloalkyl refers to a substituent in which the ring carbon is substituted with heteroatoms such as nitrogen, sulfur, oxygen, and the like.
- a saturated or unsaturated 7 to 11 membered bicyclic heterocyclic ring or a stable nonaromatic 3 to 8 membered monocyclic heterocyclic ring is used. Meaning, it can be fused, spiro or crosslinked to form additional rings.
- Each heterocycle consists of one or more carbon atoms and one to four heteroatoms.
- Heterocycloalkyl may be bonded to any inward ring that creates a stable structure.
- Preferred examples include furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isothiazole, tria Sol, thiadiazole, pyran, pyridine, piperidine, morpholine, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine and the like, but are not limited thereto.
- aryl means an aromatic substituent having at least one ring having a covalent pi electron field and comprising carbocyclic aryl (eg phenyl) and heterocyclic aryl (eg pyridine).
- carbocyclic aryl eg phenyl
- heterocyclic aryl eg pyridine
- the term includes monocyclic or fused ring polycyclic (ie rings that divide adjacent pairs of carbon atoms) groups.
- the aryl group may be carbocyclic or optionally contain 1 to 4 heteroatoms (eg, nitrogen, sulfur or oxygen) in the aromatic ring, also referred to as "heteroaryl”.
- aryl or heteroaryl examples include phenyl, naphthyl, pyridyl, pyrimidyl, pyrrolyl, isothiazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridazinyl, tria Genyl, quinazolinyl, thiazolyl, benzothiophenyl, furanyl, imidazolyl, thiophenyl, and the like, but are not limited thereto.
- the cycloalkyl, heterocycloalkyl, aryl and heteroaryl may be optionally substituted, examples of the substituent are hydroxy, halogen, thiol, cyano, nitro, amino, acylamino, C 1 -C 10 alkylthio, C 4 -C 10 arylthio, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 4 -C 10 aryloxy, C 1 -C 10 alkylcarbonyloxy, C 4 -C 10 arylcarbonyloxy, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyloxy, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 4 -C 10 aryl, carboxylate, aminocarbonyl, C 1- C 10 alkylcarbonyl, C 3 -C 8 cycloalkylcarbonyl, C 3 -C 8 heterocycloalkylcarbon
- Particularly preferred examples of the compounds according to the invention include, but are not limited to, those of Table 1 below.
- the naphthoquinone compounds used in the compositions according to the invention may be prepared by the methods disclosed in WO06 / 088315 and WO06 / 020719, and are based on other known methods and / or techniques in the field of organic synthesis. It can be produced by various methods. Based on the above methods, various derivatives can be synthesized using an appropriate synthesis method according to the type of substituents.
- the term "deafness” may include preneural hearing loss and sensorineural hearing loss, and preferably, an abnormality of the auditory nerve or central nervous system that causes an abnormality in the function of detecting the sound of the cochlea or transmits a stimulus caused by the sound to the brain. It includes sensorineural hearing loss, which is caused by aging, and in particular, senile hearing loss due to aging and hearing loss due to toxic drugs.
- the naphthoquinone compounds used in the composition according to the present invention exhibited a recovery effect of the auditory brainstem response threshold in the animal model of deafness due to senile hearing loss and toxic drugs, inhibits cell death of auditory hair cells and HMGB1 (high- Inhibition of increased expression of mobility group box-1) was shown to protect hearing damage caused by aging or toxic drugs.
- composition according to the present invention can be used as a pharmaceutical composition for the treatment or prevention of hearing loss.
- compositions according to the invention can be administered orally (eg, by taking or inhaling) or parenterally (eg by injection, transdermal absorption, rectal administration), and the injection can be administered, for example, by intravenous injection. , Intracutaneous injection, intramuscular injection or intraperitoneal injection.
- the pharmaceutical composition according to the present invention may be used as tablets, capsules, granules, fine subtilae, powders, sublingual tablets, suppositories, ointments, injections, emulsions, suspensions, syrups, sprays and the like.
- the pharmaceutical compositions according to the present invention in various forms can be prepared by known techniques using pharmaceutically acceptable carriers commonly used in each formulation.
- Examples of pharmaceutically acceptable carriers include excipients, binders, disintegrating agents, lubricants, preservatives, antioxidants, isotonic agents, buffers, coatings, sweeteners, solubilizers, bases, dispersants, wetting agents , Suspending agents, stabilizers, coloring agents and the like.
- composition according to the present invention can be used as a dietary supplement for the improvement or prevention of hearing loss.
- the health functional food of the present invention may be prepared by appropriately using a food acceptable carrier such as fillers, extenders, binders, wetting agents, disintegrants, sweeteners, fragrances, preservatives, surfactants, lubricants, excipients, etc. Can be.
- a food acceptable carrier such as fillers, extenders, binders, wetting agents, disintegrants, sweeteners, fragrances, preservatives, surfactants, lubricants, excipients, etc. Can be.
- the content of the naphthoquinone-based compound varies depending on the form of the health functional food, but the concentration is about 0.01 to 100% by weight.
- Figure 2 is a graph measuring the threshold change of the auditory brainstem response between experimental groups in 15 months experimental animals.
- Figure 3 is a graph measuring the threshold change of the auditory brainstem response between the experimental group in 18 months experimental animals.
- Figure 4 is a graph measuring the threshold change of the auditory brainstem response between experimental groups in 21 months experimental animals.
- Figure 5 is a graph measuring the threshold change of the auditory brainstem response between experimental groups in 24 months experimental animals.
- Figure 6 is a diagram showing the inhibitory effect of ⁇ - rapacon ( ⁇ L) on cell death of auditory hair cells by aging.
- FIG. 7 is a diagram showing the inhibitory effect of ⁇ - rapacon ( ⁇ L) on the increased expression of HMGB1 by aging.
- Figure 8 is a graph measuring the threshold change of auditory brainstem response between experimental groups in 6-week-old experimental animals.
- FIG. 9 is a graph showing the inhibitory effect of ⁇ -rapacone ( ⁇ L) on apoptosis of auditory hair cells by cisplatin (CDDP).
- FIG. 10 is a diagram showing the inhibitory effect of ⁇ -rapacone ( ⁇ L) on the increased expression of inflammatory mediators by cisplatin (CDDP).
- FIG. 11 is a graph showing the inhibitory effect of ⁇ -Rapacon ( ⁇ L) on increased release of HSP60 by cisplatin (CDDP) in rats.
- FIG. 12 is a graph showing the inhibitory effect of ⁇ -Rapacon ( ⁇ L) on increased release of HSP60 by cisplatin (CDDP) in HEI-OC1 cells.
- Figure 13 is a graph showing the role of HSP60 in apoptosis of auditory hair cells by cisplatin (CDDP).
- ⁇ -rapacone ⁇ L
- CDDP cisplatin
- C57BL / 6 mice a well-known model for hearing loss according to age. Twelve-month-old C57BL / 6 mice were purchased directly from a central laboratory animal company and reared up to 24 months, and hearing was measured every three months. All rats used in the experiment were raised in a sterile animal room with constant temperature (22-26 ° C) and constant humidity (55-60%).
- the experimental group was fed a diet containing the normal diet (control group), the diet limited to 70% (caloric restriction group: CR group) and the feed containing 0.06% ⁇ - rapacon (Compound 1). All experiments were divided by ( ⁇ L group).
- the reference hearing level of the 12-month experimental animal was significantly higher than the average hearing threshold of 10 dB SPL in the first half compared to that of the 2-month experimental animal.
- the threshold change of auditory brainstem response was measured by three groups.
- the threshold values of the auditory brainstem response measured at 4, 8, 16, and 32 kHz were 70 ⁇ 10, 33.33 ⁇ 5.77, 40 ⁇ 10, and 50 ⁇ 10 dB SPL, respectively.
- the auditory brainstem threshold was restored significantly ( p ⁇ 0.05).
- the thresholds of the auditory brainstem response measured at 4, 8, 16 and 32 kHz in the control group were 80 ⁇ 10 and 63.33, respectively. ⁇ 5.77, 76.67 ⁇ 5.77 and 80 ⁇ 10 dB SPL, 80 ⁇ 0, 46.67 ⁇ 11.55, 56.67 ⁇ 11.55 and 66.67 ⁇ 11.55 dB SPL in the ⁇ L group, respectively, 73.33 ⁇ 5.77, 43.33 ⁇ 5.77, 43.33 in the CR group, respectively. ⁇ 5.77 and 56.67 ⁇ 5.77 dB SPL showed statistically significant recovery of auditory brainstem response threshold at 8-32 kHz compared to the control group ( p ⁇ 0.05).
- the thresholds for the auditory brainstem response measured at 4, 8, 16 and 32 kHz in the control group were 86.67 ⁇ 5.77, respectively. 73.33 ⁇ 5.77, 73.33 ⁇ 5.77 and 80 ⁇ 0 dB SPL, and 56.67 ⁇ 5.77, 46.67 ⁇ 5.77, 53.33 ⁇ 15.28 and 46.67 ⁇ 5.77 dB SPL in the ⁇ L group, respectively.
- the threshold of auditory brainstem response was recovered ( p ⁇ 0.05), and in the CR group, 73.33 ⁇ 5.77, 56.67 ⁇ 5.77, 56.67 ⁇ 5.77, and 73.33 ⁇ 11.55 dB SPL, respectively.
- the auditory brainstem threshold was significantly recovered ( p ⁇ 0.05).
- the thresholds of the auditory brainstem response measured at 4, 8, 16 and 32 kHz in the control group were 86.67 ⁇ 5.77 and 83.33, respectively.
- a showed a recovery (p ⁇ 0.05), except in 8 ⁇ 32 kHz 4 kHz and recovered the auditory brainstem response threshold than 30 dB SPL than the control group.
- CR group showed 83.33 ⁇ 5.77, 63.33 ⁇ 5.77, 83.33 ⁇ 5.77 and 83.33 ⁇ 11.55 dB SPL, which showed statistically significant recovery of auditory brainstem threshold only in the 8 kHz region compared to the control group ( p ⁇ 0.05).
- TUNEL terminal deoxynucleotidyl transferase
- morphological modification of mitochondria was performed through transmission electron microscope (TEM) in three experimental groups of 24 months old animals to confirm whether ⁇ -lapacon inhibited the loss of mitochondria due to aging. It was.
- Tissue staining was performed to investigate the effect of ⁇ -rapacone on the expression of HMGB1, which is known to be important for mitochondrial damage and morphology.
- the control group and the CR group of 21-month-old experimental animals were significantly increased in HMGB1 expression throughout the entire inner ear compared to the 2-month-old experimental animals, while in the 21-month-old ⁇ L group, the other experimental group. It was observed that the expression of HMGB1 was significantly reduced than the above.
- ⁇ -rapacone inhibited the expression of HMGB1 with aging and inhibited cell death and morphological changes in mitochondria of cells in the inner ear tissues, thereby protecting the hearing damage caused by aging. .
- mice Six-week-old C57BL / 6 mice were used in this experiment. All rats used in the experiment were raised in a sterile animal room with constant temperature (22-26 ° C) and constant humidity (55-60%).
- the experimental group was injected with PBS only (control), cisplatin (4 mg / kg / day) intraperitoneally for 4 days (CDDP group), ⁇ -rapacone (10 mg / kg, 20 mg / kg and 40 mg / kg).
- CDDP group cisplatin
- ⁇ -rapacone 10 mg / kg, 20 mg / kg and 40 mg / kg.
- the experiment was divided into a group injected with cisplatin for 4 days and a group injected with only ⁇ -rapacone (40 mg / kg) ( ⁇ L group).
- the ABR test measured the amount of change in threshold before and after injection of all drugs in the same way as Experimental Example 1-2, and the comparison of ABR threshold change between groups was one-way analysis of variance (ANOVA). ), The test was performed, and a P value of 0.05 or less was considered meaningful.
- the threshold of auditory brainstem response increased by 30 dB SPL or more in all regions, whereas in the experimental group given ⁇ -rapacone and cisplatin, the CDDP group in all regions.
- Statistically significant recovery of auditory brainstem response threshold was found ( p ⁇ 0.05).
- the control group did not show any significant changes in the threshold of auditory brainstem response, and in the ⁇ L group, only slight changes in the threshold of auditory brainstem response were observed in the ⁇ L group.
- ⁇ -rapacon's hearing damage caused by cisplatin directly inhibits cell death of auditory hair cells
- various concentrations of ⁇ -rapacon were treated in HEI-OC1 cells, the auditory hair cell line, 30 minutes before Cell viability for cisplatin was then measured by the MTT method.
- the explants of the Corti organs showed changes in the shape and arrangement of exogenous and internal hair cells during cisplatin treatment, whereas in the experimental group treated with ⁇ -lapacon like cisplatin, the shape and arrangement of auditory hair cells. It was confirmed that the maintenance similar to this control.
- inflammatory mediators known to be important factors for hearing loss by cisplatin was confirmed by PCR. After treatment with various concentrations of ⁇ -rapacone 30 minutes before, expression of inflammatory mediators by cisplatin was measured by PCR.
- cisplatin-treated HEI-OC1 cells showed increased expression of cytokines causing inflammation such as TNF- ⁇ , IL-6 and HSP60 and inflammation mediators such as TLR2 and TLR4 as shown in FIG. 10. It was confirmed that these were also inhibited dependently on the concentration of ⁇ -rapacone.
- HSP60 which is present in mitochondria, is known to bind to TLR2 or TLR4 and cause a strong inflammatory response when released extracellularly. Therefore, as a result of confirming the release amount of HSP60 in rats and HEI-OC1 cells by ELISA method, the release of HSP60 was significantly increased in cisplatin-treated mice and HEI-OC1 cells as shown in FIGS. 11 and 12, respectively. p ⁇ 0.05). However, HSP60 release was reduced in mice and HEI-OC1 cells treated with ⁇ -rapacone, depending on the concentration of ⁇ -rapacone.
- HSP60 was expressed in mitochondria in normal cells (control), whereas most of HSP60 was expressed in cytoplasm in cisplatin-treated cells. In the cells treated with rapacone and cisplatin, HSP60 was expressed only in mitochondria as in normal cells.
- HSP60 antibody was treated with cisplatin and the cell viability was measured by MTT method. As shown in FIG. 13, HEI by cisplatin -OC1 cell death was inhibited by treatment with HSP60 antibody ( p ⁇ 0.05).
- HMGB1 along with HSP60, is known as an important mediator of TLR activity and subsequent inflammatory response. Therefore, as a result of confirming the extracellular release of HMGB1 by ELISA method, it was confirmed that the excess HMGB1 is released extracellularly in the HEI-OC1 cells treated with cisplatin, as shown in FIG. It was confirmed that the decrease was dependent ( p ⁇ 0.05).
- ⁇ -rapacone was found to have an excellent effect on the protection of hearing hair loss and hearing damage caused by cisplatin by inhibiting the expression of various inflammatory mediators.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Detergent Compositions (AREA)
Abstract
Description
Claims (15)
- 하기 화학식 1 또는 2의 화합물, 그의 약제학적으로 허용되는 염, 프로드럭 (prodrug), 용매화물 또는 이성질체를 포함하는 난청의 치료 또는 예방을 위한 조성물:상기 식에서,R1 내지 R6은 각각 독립적으로 수소, 히드록시, 할로겐, 아미노, 치환 또는 비치환된 C1-C10 알킬아미노, 치환 또는 비치환된 C1-C10 디알킬아미노, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C2-C10 알케닐, 치환 또는 비치환된 C2-C10 알키닐, 치환 또는 비치환된 C1-C10 알콕시, 치환 또는 비치환된 C1-C10 알콕시카르보닐, 치환 또는 비치환된 C1-C10 아실, 치환 또는 비치환된 C3-C8 시클로알킬, 치환 또는 비치환된 C3-C8 헤테로시클로알킬, 치환 또는 비치환된 C4-C10 아릴, 치환 또는 비치환된 C4-C10 헤테로아릴, 및 치환 또는 비치환된 -(CH2)n-아릴로 이루어진 군에서 선택되거나, 이들 중 두 개의 치환기가 상호 연결되어 이루어진 이중결합이거나 치환 또는 비치환된 C3-C6의 환구조일 수 있으며, 상기 환구조는 포화 구조 또는 부분적 또는 전체적 불포화 구조일 수 있고, 여기서 치환기는 히드록시, 할로겐, C1-C10 알킬, C2-C10 알케닐, C2-C10 알키닐, C1-C10 알콕시, C1-C10 알콕시카르보닐, C1-C10 알킬아미노, C3-C8 시클로알킬, C3-C8 헤테로시클로알킬, C4-C10 아릴, 및 C4-C10 헤테로아릴로 이루어진 군에서 선택된 하나 이상일 수 있으며;R7 내지 R10은 각각 독립적으로 수소, 히드록시, 할로겐, 아미노, 치환 또는 비치환된 C1-C10 알킬아미노, 치환 또는 비치환된 C1-C10 디알킬아미노, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C2-C10 알케닐, 치환 또는 비치환된 C2-C10 알키닐, 치환 또는 비치환된 C1-C10 알콕시, 치환 또는 비치환된 C1-C10 알콕시카르보닐, 치환 또는 비치환된 C1-C10 아실, 치환 또는 비치환된 C3-C8 시클로알킬, 치환 또는 비치환된 C3-C8 헤테로시클로알킬, 치환 또는 비치환된 C4-C10 아릴, 치환 또는 비치환된 C4-C10 헤테로아릴, 및 치환 또는 비치환된 -(CH2)n-아릴로 이루어진 군에서 선택되거나, 이들 중 두 개의 치환기가 상호 연결되어 치환 또는 비치환된 C3-C6의 환구조일 수 있으며, 상기 환구조는 포화 구조 또는 부분적 또는 전체적 불포화 구조일 수 있고, 여기서 치환기는 히드록시, 할로겐, C1-C10 알킬, C2-C10 알케닐, C2-C10 알키닐, C1-C10 알콕시, C1-C10 알콕시카르보닐, C1-C10 알킬아미노, C3-C8 시클로알킬, C3-C8 헤테로시클로알킬, C4-C10 아릴, 및 C4-C10 헤테로아릴로 이루어진 군에서 선택된 하나 이상일 수 있으며;X는 O, S 또는 NR'이고, 여기서 R'는 수소 또는 C1-C6 알킬이고;Y는 C, S, N 또는 O이고, 여기서 Y가 S 또는 O인 경우 R5 및 R6는 어떠한 치환기도 아니며, Y가 N인 경우 R5은 수소 또는 C1-C6 알킬이고 R6은 어떠한 치환기도 아니며;m은 0 또는 1이고, m이 0인 경우 그의 인접 탄소원자들은 직접 결합에 의해 환형구조를 이루며,n은 0 내지 10의 정수이다.
- 제1항에 있어서,X는 O 또는 S이고,Y는 C 또는 O인 것을 특징으로 하는 조성물.
- 제1항에 있어서,R1 내지 R6은 각각 독립적으로 수소, 히드록시, 할로겐, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C2-C10 알케닐, 치환 또는 비치환된 C1-C10 알콕시, 및 -(CH2)n-페닐로 이루어진 군에서 선택되거나, R1 및 R4 또는 R2 및 R3가 상호 연결되어 이루어진 이중결합 또는 C4-C6의 환구조일 수 있고, 여기서 치환기는 C1-C10 알킬인 것을 특징으로 하는 조성물.
- 제1항에 있어서,R7 내지 R10은 각각 독립적으로 수소, 히드록시, 할로겐, 치환 또는 비치환된 C1-C10 알킬, 및 치환 또는 비치환된 C1-C10 알콕시로 이루어진 군에서 선택되는 것을 특징으로 하는 조성물.
- 제8항에 있어서,R11 내지 R18은 각각 독립적으로 수소, 히드록시, 할로겐, C1-C10 알킬, C2-C10 알케닐, C2-C10 알키닐, C1-C10 알콕시, C3-C8 시클로알킬, 또는 페닐인 것을 특징으로 하는 조성물.
- 제7항에 있어서,R1 및 R2는 C1-C10 알킬이고,R3 내지 R10은 수소이며,X는 O이고,Y는 C인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 난청이 노화에 의한 노인성 난청인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 난청이 이독성 약물에 의한 난청인 것을 특징으로 하는 조성물.
- 제1항 내지 제12항 중 어느 한 항에 있어서, 조성물이 약제학적으로 허용되는 담체를 함께 포함하는 약제학적 조성물인 것을 특징으로 하는 조성물.
- 제1항 내지 제12항 중 어느 한 항에 있어서, 조성물이 식품학적으로 허용되는 담체를 함께 포함하는 건강기능식품인 것을 특징으로 하는 조성물.
- 하기 화학식 1 또는 2의 화합물, 그의 약제학적으로 허용되는 염, 프로드럭 (prodrug), 용매화물 또는 이성질체의 난청의 치료 또는 예방을 위한 용도:상기 식에서,R1 내지 R6은 각각 독립적으로 수소, 히드록시, 할로겐, 아미노, 치환 또는 비치환된 C1-C10 알킬아미노, 치환 또는 비치환된 C1-C10 디알킬아미노, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C2-C10 알케닐, 치환 또는 비치환된 C2-C10 알키닐, 치환 또는 비치환된 C1-C10 알콕시, 치환 또는 비치환된 C1-C10 알콕시카르보닐, 치환 또는 비치환된 C1-C10 아실, 치환 또는 비치환된 C3-C8 시클로알킬, 치환 또는 비치환된 C3-C8 헤테로시클로알킬, 치환 또는 비치환된 C4-C10 아릴, 치환 또는 비치환된 C4-C10 헤테로아릴, 및 치환 또는 비치환된 -(CH2)n-아릴로 이루어진 군에서 선택되거나, 이들 중 두 개의 치환기가 상호 연결되어 이루어진 이중결합이거나 치환 또는 비치환된 C3-C6의 환구조일 수 있으며, 상기 환구조는 포화 구조 또는 부분적 또는 전체적 불포화 구조일 수 있고, 여기서 치환기는 히드록시, 할로겐, C1-C10 알킬, C2-C10 알케닐, C2-C10 알키닐, C1-C10 알콕시, C1-C10 알콕시카르보닐, C1-C10 알킬아미노, C3-C8 시클로알킬, C3-C8 헤테로시클로알킬, C4-C10 아릴, 및 C4-C10 헤테로아릴로 이루어진 군에서 선택된 하나 이상일 수 있으며;R7 내지 R10은 각각 독립적으로 수소, 히드록시, 할로겐, 아미노, 치환 또는 비치환된 C1-C10 알킬아미노, 치환 또는 비치환된 C1-C10 디알킬아미노, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C2-C10 알케닐, 치환 또는 비치환된 C2-C10 알키닐, 치환 또는 비치환된 C1-C10 알콕시, 치환 또는 비치환된 C1-C10 알콕시카르보닐, 치환 또는 비치환된 C1-C10 아실, 치환 또는 비치환된 C3-C8 시클로알킬, 치환 또는 비치환된 C3-C8 헤테로시클로알킬, 치환 또는 비치환된 C4-C10 아릴, 치환 또는 비치환된 C4-C10 헤테로아릴, 및 치환 또는 비치환된 -(CH2)n-아릴로 이루어진 군에서 선택되거나, 이들 중 두 개의 치환기가 상호 연결되어 치환 또는 비치환된 C3-C6의 환구조일 수 있으며, 상기 환구조는 포화 구조 또는 부분적 또는 전체적 불포화 구조일 수 있고, 여기서 치환기는 히드록시, 할로겐, C1-C10 알킬, C2-C10 알케닐, C2-C10 알키닐, C1-C10 알콕시, C1-C10 알콕시카르보닐, C1-C10 알킬아미노, C3-C8 시클로알킬, C3-C8 헤테로시클로알킬, C4-C10 아릴, 및 C4-C10 헤테로아릴로 이루어진 군에서 선택된 하나 이상일 수 있으며;X는 O, S 또는 NR'이고, 여기서 R'는 수소 또는 C1-C6 알킬이고;Y는 C, S, N 또는 O이고, 여기서 Y가 S 또는 O인 경우 R5 및 R6는 어떠한 치환기도 아니며, Y가 N인 경우 R5은 수소 또는 C1-C6 알킬이고 R6은 어떠한 치환기도 아니며;m은 0 또는 1이고, m이 0인 경우 그의 인접 탄소원자들은 직접 결합에 의해 환형구조를 이루며,n은 0 내지 10의 정수이다.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10841215.6A EP2520294B1 (en) | 2009-12-28 | 2010-12-27 | Composition including a naphthoquinone derivative for treating and preventing hearing loss |
JP2012547005A JP5564118B2 (ja) | 2009-12-28 | 2010-12-27 | ナフトキノン系化合物を含む難聴の治療又は予防のための組成物 |
US13/519,512 US20120289577A1 (en) | 2009-12-28 | 2010-12-27 | Composition for treating or preventing hearing loss comprising naphthoquinone-based compounds |
CN2010800598636A CN102753165A (zh) | 2009-12-28 | 2010-12-27 | 包含萘醌基化合物的、用于治疗或预防听力损失的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0131810 | 2009-12-28 | ||
KR20090131810 | 2009-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011081383A2 true WO2011081383A2 (ko) | 2011-07-07 |
WO2011081383A3 WO2011081383A3 (ko) | 2011-11-17 |
Family
ID=44226994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/009369 WO2011081383A2 (ko) | 2009-12-28 | 2010-12-27 | 나프토퀴논계 화합물을 포함하는 난청의 치료 또는 예방을 위한 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120289577A1 (ko) |
EP (1) | EP2520294B1 (ko) |
JP (1) | JP5564118B2 (ko) |
KR (1) | KR101495223B1 (ko) |
CN (1) | CN102753165A (ko) |
WO (1) | WO2011081383A2 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI832069B (zh) * | 2020-07-10 | 2024-02-11 | 南韓商娜迪安生物公司 | 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物 |
CN113892460A (zh) * | 2021-09-29 | 2022-01-07 | 滨州医学院 | Nod-b6重组近交系小鼠模型的构建方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969163A (en) | 1996-02-20 | 1999-10-19 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth |
WO2006020719A2 (en) | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Aminoacid conjugates of beta - lapachone for tumor targeting |
WO2006088315A1 (en) | 2005-02-16 | 2006-08-24 | Md Bioalpha Co., Ltd. | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1574507A3 (en) | 1999-04-30 | 2005-10-26 | SLIL Biomedical Corporation | Furo- and pyrano-naphthoquinones and their use in the treatment of cancer |
WO2004093870A1 (en) * | 2003-03-20 | 2004-11-04 | Pharmacia Corporation | Treatment and prevention of otic disorders |
WO2008066300A1 (en) * | 2006-11-27 | 2008-06-05 | Mazence Inc. | Naphthoquinone-based pharmaceutical composition for treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases |
WO2008066295A1 (en) * | 2006-11-27 | 2008-06-05 | Mazence Inc. | Pharmaceutical composition containing naphthoquinone-based compound for intestine delivery system |
KR20080047959A (ko) * | 2006-11-27 | 2008-05-30 | 주식회사 엠디바이오알파 | 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물 |
JP2011500557A (ja) * | 2007-10-11 | 2011-01-06 | マゼンス インコーポレイテッド | ナフトキノン系化合物の微粒化粒子を含有する医薬組成物 |
US20110142834A1 (en) * | 2008-05-15 | 2011-06-16 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
-
2010
- 2010-12-27 US US13/519,512 patent/US20120289577A1/en not_active Abandoned
- 2010-12-27 KR KR20100135283A patent/KR101495223B1/ko not_active IP Right Cessation
- 2010-12-27 CN CN2010800598636A patent/CN102753165A/zh active Pending
- 2010-12-27 JP JP2012547005A patent/JP5564118B2/ja not_active Expired - Fee Related
- 2010-12-27 EP EP10841215.6A patent/EP2520294B1/en not_active Not-in-force
- 2010-12-27 WO PCT/KR2010/009369 patent/WO2011081383A2/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969163A (en) | 1996-02-20 | 1999-10-19 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth |
WO2006020719A2 (en) | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Aminoacid conjugates of beta - lapachone for tumor targeting |
WO2006088315A1 (en) | 2005-02-16 | 2006-08-24 | Md Bioalpha Co., Ltd. | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases |
Non-Patent Citations (1)
Title |
---|
See also references of EP2520294A4 |
Also Published As
Publication number | Publication date |
---|---|
EP2520294B1 (en) | 2015-02-18 |
KR101495223B1 (ko) | 2015-02-26 |
CN102753165A (zh) | 2012-10-24 |
WO2011081383A3 (ko) | 2011-11-17 |
JP5564118B2 (ja) | 2014-07-30 |
EP2520294A2 (en) | 2012-11-07 |
JP2013515765A (ja) | 2013-05-09 |
US20120289577A1 (en) | 2012-11-15 |
EP2520294A4 (en) | 2013-09-11 |
KR20110076793A (ko) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009148279A9 (ko) | 바이러스 억제제로서 유용한 트리테르페노이드계 화합물 | |
WO2011155803A2 (ko) | 청각보호 작용을 하는 신규 화합물 | |
WO2019231220A1 (ko) | 2,3,5-치환된 싸이오펜 화합물의 유방암 예방, 개선 또는 치료 용도 | |
WO2014058160A1 (ko) | 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 또는 피로회복용 조성물 | |
WO2020141828A2 (en) | Anticancer compositions comprising immune checkpoint inhibitors | |
WO2011081383A2 (ko) | 나프토퀴논계 화합물을 포함하는 난청의 치료 또는 예방을 위한 조성물 | |
WO2009148280A2 (ko) | 바이러스 억제제로서 유용한 디아릴 헤파토노이드계 화합물 | |
WO2022045520A1 (ko) | 페난트로인돌리지딘 및 페난트로퀴놀리지딘 알칼로이드 유도체, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 코로나바이러스감염증-19 치료용 조성물 | |
AU2019381050B2 (en) | Anticancer composition | |
WO2019245194A1 (ko) | Naprt 음성 암 치료용 신규 화합물 및 이를 포함하는 조성물 | |
WO2015102205A1 (ko) | 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물 | |
WO2023027540A1 (ko) | 진세노사이드 rc를 포함하는 근육 질환의 예방, 개선 또는 치료용 조성물 | |
WO2015111971A1 (ko) | Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 | |
WO2019098630A1 (ko) | 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
WO2021010728A1 (ko) | 골질환 예방 또는 치료용 약학 조성물 | |
WO2022025482A1 (ko) | 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물 | |
AU2019418259B2 (en) | Anticancer compositions comprising immune checkpoint inhibitors | |
WO2022005228A1 (ko) | 3-케토아실 coa 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
WO2023121011A1 (ko) | 아피제닌 및 항산화제를 포함하는 뇌질환 치료용 약학적 복합 조성물 | |
WO2024111897A1 (ko) | Prd-2001을 포함하는 암 예방 또는 치료용 약학적 조성물 | |
WO2021206498A1 (ko) | 항코로나바이러스능을 가지는 플라보노이드 배당체 | |
WO2024101918A1 (ko) | 리포-하이드록삼산 유도체 및 이의 약학적 용도 | |
WO2023214836A1 (ko) | 신규 베르베린 유사체 및 이의 용도 | |
WO2022103201A1 (ko) | 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2023048506A1 (ko) | 카르니틴 아실카르니틴 운반자 억제제 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080059863.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10841215 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012547005 Country of ref document: JP Ref document number: 13519512 Country of ref document: US Ref document number: 2010841215 Country of ref document: EP |